Please see what you are clicking on foxbusiness.com.
Hims & Hers Health announced on Tuesday that it will bundle Telehealth Platform membership and Wegovy through a new collaboration with drug maker Novo Nordisk.
The bundle offers all doses combined with Novo Nordisk's popular weight loss medication with HIMS & HERS membership, providing “24/7 care, ongoing clinical support and access to nutrition guidance.”
“We are thrilled to work with Novo Nordisk, a groundbreaking portfolio of clinical medicine and drugs,” Hims & her CEO Andrew Dudum said in a statement. “We share our vision for what consumer-centric healthcare looks like, and this is just the first step in delivering that future.”
Hims & Hers shares rose 25% on the news.
This bundle offers all dosages combined with Novo Nordisk's popular weight loss pills with HIMS & HERS membership. (Lightrocket via PIOTR SWAT/SOPA Images/Getty Images/Getty Images)
It comes with a starting price of $599 each month. Novocare Pharmacy from Novo Nordisk, a direct-to-patient online pharmacy targeting Wegovy patients with cash salaries published last month, is available directly from the Telehealth Company's platform as part of the partnership.
Novo Nordisk cuts half price for cash-paying consumers
Hims & Hers and Novo Nordisk will be launching bundles this week on the Telehealth Company platform.
“Based on Hims & Hers' existing suite of weight loss solutions, you can access all of Wegovy's dose strength with a high quality pen for self-paying patients,” says Hims & Hers.
Hims & Hers and Novo Nordisk will be launching bundles this week on the Telehealth Company platform. (Michael Siluk/UCG/Universal Images Group Getty Images/Getty Images)
Click here to get your Fox business on the go
In addition to the bundle, HIMS & HERS said the two companies are in the process of devising a roadmap that combines the “innovative treatments” of Danish drug makers with the “ability to scale access to quality care” of the TeleHealth platform.
Novo Nordisk in Copenhagen, Denmark. (Reuters/Tom Little/File Photo/Reuters Photo)
Two other telehealth companies, RO and Life MD, announced a partnership announced on Tuesday, similar to Novo Nordisk.
Ozempic, Wegovy among drugs subject to Medicare price control
Wegovy, along with Novo's Ozempic and Eli Lilly's Zepbound and Mounjaro, is one of the very popular GLP-1 drugs in weight loss in recent years.
| Ticker | safety | last | change | change % |
|---|---|---|---|---|
| Hem | Hims & Hers Health | 36.16 | +3.06 |
+9.24% |
| NVO | Novo Nordisk a/s | 65.62 | -0.78 |
-1.17% |
